Eisai
VC Fund
Tokyo, Japan
Eisai is a human healthcare company that provides products and services to its patients and their families under any healthcare system. They specialize in an integrated pharmaceutical business that operates in business groups and focuses on oncology and neurology, dementia-related diseases, and neurodegenerative diseases.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Eisai invests in
Stages Eisai invests in
Countries Eisai invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Round size
- Series A
- $3M–$51M
- Series C
- $881k–$100M
Investment Focus
Industry
- Medical 9 (45%)
- Biotechnology 9 (45%)
- Health Care 8 (40%)
- Therapeutics 6 (30%)
- Life Science 5 (25%)
Stage
- Series A 5 (25%)
- Series C 3 (15%)
- Grant 2 (10%)
- Corporate Round 2 (10%)
- Venture - Series Unknown 2 (10%)
Country
- Japan 5 (25%)
- United States 5 (25%)
- China 1 (5%)
- Finland 1 (5%)
- Ireland 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chad Swanson
Executive Director, Neurology Business Group; Clinical Research
|
Executive Director, Neurology Business Group; Clinical Research | Total investments: 0 | Find email | |
Eran Nadav
Business Development Director
|
Business Development Director | Total investments: 9 | Find email | |
Harald Hampel
Chief Medical Officer, Senior Vice President, Neurology
|
Chief Medical Officer, Senior Vice President, Neurology | Total investments: 0 | Find email | |
Haruo Naito
CEO
|
CEO | Total investments: 0 | Find email | |
Stewart Geary
Deputy Director
|
Deputy Director | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Head Diagnostics
|
Head Diagnostics is a life sciences technology company. | Grant / Jul 12, 2026 | |
Medefer
|
At Medefer, we want to be the world’s most patient-focused virtual health serviceWe are on a mission to help patients get better faster. We are starting by partnering with the NHS to build the best outpatient process, helping assess patients more quickly.To do this work with our partners, we provide technology-enabled clinical and operationalexpertise, making it better for patients, healthcare professionals and the NHS. | Grant / Jul 12, 2026 | |
Beren Therapeutics
|
Beren Therapeutics is a biotechnology company that develops innovative therapies to make them accessible to every patient. The company was founded in 2020 and is based in Thousand Oaks, CA. | $135M / Venture - Series Unknown / Jun 10, 2026 | |
Seed Therapeutics
|
Seed Therapeutics is a biotech company that focuses on harnessing and engineering molecules. | $30M / Series A / Aug 06, 2024 | |
|
Seed Therapeutics
|
Seed Therapeutics is a biotech company that focuses on harnessing and engineering molecules. | $30M / Series A / Aug 06, 2024 | |
RecoMed
|
RecoMed is South Africa’s largest and fastest growing online healthcare booking platform and marketplace. The company’s online booking platform and the marketplace is its core product, and it has developed white-labelled solutions for, among others, Discovery, Medicross (owned by Netcare) and Clicks.RecoMed’s mobile-friendly platform helpspatients quickly find and make appointments with a range of healthcare providers, 24/7, without any phone calls or paperwork. RecoMed seamlessly connects doctors and patients in real-time and is a strong consumer and B2B platform business that reaches stakeholders across the healthcare, life insurance and corporate wellness ecosystem. | Corporate Round / Mar 07, 2024 | |
Casma Therapeutics
|
Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs. | $46M / Series C / Nov 15, 2022 | |
Lifenet Insurance Company
|
LIFENET INSURANCE COMPANY offers a range of insurance underwriting and asset management solutions. Its insurance products include death, medical, and disability insurance. The company also provides health counselling services. LIFENET INSURANCE COMPANY was founded in October 2006. | $2.2M / Post-IPO Equity / Aug 09, 2022 | |
Ractigen Therapeutics
|
Ractigen is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation(RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need. | $30M / Series A / Jan 27, 2022 | |
Prism BioLab
|
PRISM provider of a therapeutic treatment for non-oncology indications.The company develops therapeutic agents that are used to cure pulmonary fibrosis, cancer and incurable diseases. | $880.8K / Series C / Oct 12, 2021 | |
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Eisai invest in?
Eisai invests primarily in Medical, Biotechnology and Health Care startups, most often at Series A and Series C stage. Most of the 20 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Eisai's check size?
Eisai typically joins rounds of $3M–$51M at Series A and $881k–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Eisai participates in.
How do I contact Eisai?
Public channels for Eisai include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Eisai?
The team at Eisai includes Chad Swanson (Executive Director, Neurology Business Group; Clinical Research), Eran Nadav (Business Development Director) and Harald Hampel (Chief Medical Officer, Senior Vice President, Neurology), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
